TrialIntegrative cancer therapies

Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Exploratory Study to Evaluate the Efficacy and Safety of HAD-B1 for Dose-Finding in EGFR Mutation Positive and Locally Advanced or Metastatic NSCLC Subjects Who Need Afatinib Therapy.

Eun-Ju Ko et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.